###begin article-title 0
Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys
###end article-title 0
###begin article-title 1
Effective Post-Exposure Treatnment of Ebola Infection
###end article-title 1
###begin p 2
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 260 271 <span type="species:ncbi:205488">Ebola virus</span>
###xml 275 290 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 344 355 <span type="species:ncbi:10141">guinea pigs</span>
###xml 377 392 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 530 541 <span type="species:ncbi:205488">Ebola virus</span>
###xml 724 729 <span type="species:ncbi:9606">human</span>
###xml 809 820 <span type="species:ncbi:205488">Ebola virus</span>
###xml 1020 1031 <span type="species:ncbi:205488">Ebola virus</span>
Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protect against Ebola virus in rhesus macaques. This antibody was previously shown to fully protect guinea pigs from infection. Four rhesus macaques were given 50 mg/kg of neutralizing human monoclonal antibody KZ52 intravenously 1 d before challenge with 1,000 plaque-forming units of Ebola virus, followed by a second dose of 50 mg/kg antibody 4 d after challenge. A control animal was exposed to virus in the absence of antibody treatment. Passive transfer of the neutralizing human monoclonal antibody not only failed to protect macaques against challenge with Ebola virus but also had a minimal effect on the explosive viral replication following infection. We show that the inability of antibody to impact infection was not due to neutralization escape. It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 316 322 <span type="species:ncbi:9606">humans</span>
###xml 520 525 <span type="species:ncbi:9606">human</span>
###xml 560 571 <span type="species:ncbi:10141">guinea pigs</span>
###xml 580 591 <span type="species:ncbi:205488">Ebola virus</span>
###xml 667 678 <span type="species:ncbi:205488">Ebola virus</span>
###xml 924 935 <span type="species:ncbi:205488">Ebola virus</span>
###xml 1114 1125 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus is one of the most feared of human pathogens with a mortality that can approach 90% and an extremely rapid disease course that can lead to death within days of infection. Antibodies able to inhibit viral infection in culture, neutralizing antibodies, can typically prevent viral infection in animals and humans when present prior to infection, at sufficient concentration. Such neutralizing antibodies may be provided through passive administration or induced by vaccination. We have previously shown that a human neutralizing antibody can protect guinea pigs against Ebola virus. However, here we show that this antibody does not protect monkeys against Ebola virus and surprisingly appears to have very little impact upon the rapid course of infection, despite being present at very high levels in the blood of the monkeys. We conclude that administering antibody prior to or immediately following exposure to Ebola virus, for example, after an accident in a research setting or a bioterrorist attack, is unlikely to be effective in preventing disease. Recent successes in protecting monkeys against Ebola virus through vaccination may be independent of antibody, or, more likely, critically dependent on the cooperation of antibody and cellular immunity.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 0 281 0 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Editor's note: The potential efficacy of pre- and post-exposure prophylaxis against Ebola virus infection, as well as the fundamentally important question of whether neutralizing bodies are important for Ebola virus resistance, is addressed by a related manuscript in this issue of</italic>
###xml 298 313 298 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Please see doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.ppat.0030002">10.1371/journal.ppat.0030002</ext-link> by Feldmann et al.</italic>
###xml 84 95 <span type="species:ncbi:205488">Ebola virus</span>
###xml 204 215 <span type="species:ncbi:205488">Ebola virus</span>
Editor's note: The potential efficacy of pre- and post-exposure prophylaxis against Ebola virus infection, as well as the fundamentally important question of whether neutralizing bodies are important for Ebola virus resistance, is addressed by a related manuscript in this issue of PLoS Pathogens. Please see doi: by Feldmann et al.
###end p 6
###begin p 7
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b001">1</xref>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b003">3</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b002">2</xref>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b004">4</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b005">5</xref>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b005">5</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b006">6</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b007">7</xref>
###xml 156 162 <span type="species:ncbi:9606">humans</span>
Passive transfer of relatively high concentrations of neutralizing antibodies can protect against challenge with a range of viruses in animal models and in humans [1-3]. Protection in some cases is in the form of sterilizing immunity, i.e., no viral replication is observed following challenge [2,4,5]. In other cases (e.g., [5,6]), some replication is observed but protection from disease is achieved, presumably because neutralizing antibody sufficiently blunts infection for T cell and innate immunity to resolve infection [7]. It might be expected that passive neutralizing antibody would be most effective against challenge with acute viruses. Many acute viral infections are resolved even in the absence of neutralizing antibody, and the blunting effect of passive antibody would provide more time for the development of effective cellular immune responses. In contrast, chronic viruses may present a greater challenge to passive antibody, since, in the absence of sterilizing immunity, there is a window of opportunity for the virus to establish a chronic infection before cellular immunity can be mobilized.
###end p 7
###begin p 8
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b008">8</xref>
###xml 105 121 105 121 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Zaire ebolavirus</named-content>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b009">9</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b008">8</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b010">10</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b010">10</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b011">11</xref>
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 13 17 <span type="species:ncbi:205488">EBOV</span>
###xml 54 60 <span type="species:ncbi:9606">humans</span>
###xml 105 121 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 339 343 <span type="species:ncbi:205488">EBOV</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 598 602 <span type="species:ncbi:205488">EBOV</span>
###xml 677 682 <span type="species:ncbi:9606">human</span>
Ebola virus (EBOV) causes a severe acute infection in humans [8]. Infection with the Ebola Zaire strain, Zaire ebolavirus (ZEBOV), produces mortality in the range of 60%-90% [9] with death generally occurring around 7-11 d following the appearance of symptoms [8]. There is a single report describing the use of convalescent sera to treat EBOV infection [10]. However, the patients in this report may have already been through the worst stages of the disease, and it is not clear that serum antibodies were responsible for their recovery [10]. Further, neutralizing antibody titers in survivors of EBOV infection tend to be rather low, although we have isolated a neutralizing human monoclonal antibody (mAb), KZ52, of good potency from a convalescent individual [11].
###end p 8
###begin p 9
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b012">12</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b013">13</xref>
###xml 527 529 527 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 559 561 558 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">90</sub>
###xml 595 597 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b011">11</xref>
###xml 598 600 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b014">14</xref>
###xml 611 613 609 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 653 655 650 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">90</sub>
###xml 712 714 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b014">14</xref>
###xml 930 931 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b006">6</xref>
###xml 51 55 <span type="species:ncbi:205488">EBOV</span>
###xml 112 122 <span type="species:ncbi:10141">guinea pig</span>
###xml 127 132 <span type="species:ncbi:10090">mouse</span>
###xml 296 306 <span type="species:ncbi:10141">guinea pig</span>
###xml 332 337 <span type="species:ncbi:9796">horse</span>
###xml 339 344 <span type="species:ncbi:9940">sheep</span>
###xml 350 354 <span type="species:ncbi:9925">goat</span>
###xml 386 390 <span type="species:ncbi:205488">EBOV</span>
###xml 407 412 <span type="species:ncbi:9606">human</span>
###xml 418 422 <span type="species:ncbi:205488">EBOV</span>
###xml 683 688 <span type="species:ncbi:9606">human</span>
###xml 912 922 <span type="species:ncbi:10141">guinea pig</span>
The ability of passive antibody to protect against EBOV has been investigated in a number of animal models. The guinea pig and mouse models use EBOVs that have been serially passaged to adapt to replication in the respective animals and are highly lethal. Protection has been demonstrated in the guinea pig model using neutralizing horse, sheep, and goat immunoglobulin G (IgG) against EBOV [12,13] and the human anti-EBOV GP mAb, IgG KZ52. This antibody neutralizes ZEBOV (1995, Kikwit) with a 50% inhibitory concentration (IC50) of 0.05-0.3 mug/ml and an IC90 of 0.5-2.6 mug/ml in Vero cells [11,14] and an IC50 of approximately 0.05-1 mug/ml and a IC90 of 0.5-2 mug/ml in primary human monocytes/macrophages [14]. We showed that when administered subcutaneously at a dosage of 25 mg/kg up to 1 h after challenge, the antibody protects against robust ZEBOV challenge (10,000 plaque-forming units [pfu]) in the guinea pig model [6].
###end p 9
###begin p 10
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b008">8</xref>
###xml 244 266 244 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Macaca fascicularis),</italic>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b015">15</xref>
###xml 410 426 410 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Macaca mulatta)</italic>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b016">16</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b013">13</xref>
###xml 1014 1016 1014 1016 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b017">17</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b018">18</xref>
###xml 1257 1259 1257 1259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1277 1279 1277 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b019">19</xref>
###xml 28 32 <span type="species:ncbi:205488">EBOV</span>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 209 215 <span type="species:ncbi:9606">humans</span>
###xml 245 264 <span type="species:ncbi:9541">Macaca fascicularis</span>
###xml 394 409 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 411 425 <span type="species:ncbi:9544">Macaca mulatta</span>
###xml 547 557 <span type="species:ncbi:10141">guinea pig</span>
###xml 608 614 <span type="species:ncbi:9796">equine</span>
###xml 789 807 <span type="species:ncbi:9541">cynomolgus monkeys</span>
###xml 889 893 <span type="species:ncbi:205488">EBOV</span>
###xml 974 980 <span type="species:ncbi:9796">equine</span>
###xml 995 1002 <span type="species:ncbi:9557">baboons</span>
###xml 1235 1242 <span type="species:ncbi:9557">baboons</span>
Macaques provide a model of EBOV infection that is likely closer to human infection. The human virus can be used directly in macaques without need for adaptation and the course of disease mirrors that seen in humans [8]. In cynomolgus macaques (Macaca fascicularis), ZEBOV infection produces a mortality rate of 100% with death occurring 6-8 d following infection with 1,000 pfu [15], while in rhesus macaques (Macaca mulatta) ZEBOV produces about 100% mortality with death occurring 7-10 d after infection with 1,000 pfu [16]. In contrast to the guinea pig experiments, the passively transferred polyclonal equine neutralizing IgG described above provided only some minor benefit in the form of a slight delay in the onset of viremia from day 5 to day 7 [13] following ZEBOV challenge of cynomolgus monkeys. No significant reduction in mortality was observed. However, protection against EBOV in primates has been observed in a low dose challenge model. Thus, neutralizing equine IgG protected baboons from <30 LD50 (50% lethal dose) ZEBOV challenge when the IgG was given up to 1 h after infection and the serum contained high neutralizing antibody titers (1:128 to 1:512) [17,18], and, similarly, neutralizing ovine serum protected baboons against 0.6 LD50 ZEBOV challenge [19].
###end p 10
###begin p 11
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 120 135 <span type="species:ncbi:9544">rhesus macaques</span>
Here, we studied the ability of passively transferred neutralizing human mAb KZ52 to protect against ZEBOV challenge in rhesus macaques. This passive transfer failed to protect the macaques against challenge with ZEBOV, and, furthermore, had a minimal effect on the explosive viral replication following infection. We showed by ELISA that antibody was present at high levels in serum of the monkeys and that neutralization escape was not responsible for the resistance of virus to antibody prophylaxis.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Plasma Viremia in Antibody-Treated Macaques
###end title 13
###begin p 14
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b002">2</xref>
###xml 646 647 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 650 651 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 669 677 669 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030009-g001">Figure 1</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b015">15</xref>
###xml 930 938 930 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030009-g001">Figure 1</xref>
###xml 52 63 <span type="species:ncbi:205488">Ebola virus</span>
###xml 148 163 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 1389 1400 <span type="species:ncbi:205488">Ebola virus</span>
To evaluate whether IgGl KZ52 could protect against Ebola virus infection in a nonhuman primate animal model, antibody was passively transferred to rhesus macaques followed by challenge with the 1995 ZEBOV (Kikwit) isolate 24 h later. Protection against virus challenge by neutralizing antibodies in naive animals often requires high doses of antibody [2]. Therefore, we used a high dose of 50 mg/kg KZ52, which was close to the maximum practically achievable. In addition, we gave a second bolus of 50 mg/kg of KZ52 on day 4 following infection. The results for the four antibody-treated animals show a steady increase in plasma viremia up to 105-107 pfu/ml on day 7 (Figure 1). These levels of plasma viremia closely parallel those seen in the control animal and typically seen in historical controls [15]. The second bolus of antibody given on day 4 did not appear to have any impact upon the rate of increase of plasma virus (Figure 1). Three of the treated animals were euthanized when moribund at day 9 or 10 post infection. The fourth treated animal showed a decrease in plasma viral load after the peak and survived to day 28 before becoming moribund when it too was euthanized. Although monkey CH46 had less severe symptoms than the other animals in the study, it was concluded that this animal, too, was suffering from disease due to ZEBOV, as evidenced, for example, by copious Ebola virus antigen in the lungs (see below).
###end p 14
###begin title 15
Serum Antibody Levels in Treated Animals
###end title 15
###begin p 16
###xml 331 338 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030009-t001">Table 1</xref>
###xml 711 712 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b006">6</xref>
###xml 757 759 755 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">90</sub>
###xml 1023 1025 1020 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">90</sub>
###xml 1129 1130 1126 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b004">4</xref>
###xml 1131 1133 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b020">20</xref>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
Serum antibody (KZ52) loads were measured 1 d before virus challenge (day -1) and 4 d after challenge but before antibody boosting (day 4) by an ELISA designed to detect KZ52 as a human antibody that has bound to immobilized ZEBOV glycoprotein. The serum KZ52 antibody levels on day 4 were in the approximate range 200-400 mug/ml (Table 1). The two control monkeys, EHD (untreated and challenged), and a negative monkey (neither treated nor challenged), had very similar background levels of reactivity to the glycoprotein and anti-human antibody as each of the treated monkeys before treatment. A 50-mg/kg dose typically produces serum mAb concentrations in animals on the order of 500 mug/ml after injection [6]. Since the neutralization titer of KZ52 (IC90) for ZEBOV is on the order of 0.5-2.5 mug/ml, depending upon the target cell and the presence of complement, the concentrations of KZ52 in the animals at the time of challenge and for the first few days were, as expected, greater than, or on the order of 100 x IC90. These concentrations typically provide sterilizing immunity against challenge by a number of viruses [4,20].
###end p 16
###begin title 17
Antibody Neutralization of Plasma Virus from Treated Animals
###end title 17
###begin p 18
###xml 481 502 480 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
One formal possibility is that the neutralizing antibody has little effect on the course of infection in the treated monkeys because of the rapid emergence of neutralization escape mutants. Accordingly, virus was isolated from a selection of plasma from day 4 (monkeys CH56, CH57, and CH83) and day 7 (monkeys CH56 and CH57). All of these viruses were sensitive to KZ52 so that essentially 100% neutralization was observed in vitro at 40 and 400 mug/ml KZ52 in a plaque assay (see Materials and Methods) using Vero E6 target cells.
###end p 18
###begin title 19
Virus Levels in Different Organs and Immunohistochemistry
###end title 19
###begin p 20
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 310 311 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 373 380 373 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030009-t002">Table 2</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b015">15</xref>
###xml 831 839 831 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030009-g002">Figure 2</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b015">15</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b021">21</xref>
###xml 1264 1266 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b024">24</xref>
###xml 1433 1435 1433 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b025">25</xref>
###xml 1407 1412 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In order to gain a better understanding of any differences in pathology between the control and antibody-treated animals, the levels of virus in different organs were surveyed postmortem. Viral levels in the liver, spleen, kidney, adrenal glands, lung, and mesenteric and inguinal lymph nodes were high (104-106 pfu/g) in the control and three of the four treated animals (Table 2). However, monkey CH46, who survived much longer than the other animals (to day 28) showed some major histopathological differences from the other infected monkeys and from the norm for ZEBOV infection [15]. Relatively low viral levels were observed in most of the organs of CH46, and none in the liver, spleen, and adrenal glands. In addition, large immunoreactive monocytes were found in the blood of monkeys CH56, CH57, and CH83, but not in CH46 (Figure 2). Typically, smaller immunoreactive monocytes are seen with ZEBOV infection [15]. The presence of large immunoreactive monocytes may simply reflect uptake of antibody-coated virions via Fc receptors and subsequent viral clearance. However, it is interesting to note that previous studies have implicated mononuclear phagocytes as vehicles for transport of filovirus particles to specific organs such as liver and spleen [21-24]. If virus particles could remain infectious following Fc receptor-mediated uptake in a subset of cells (compare DC-SIGN mediated uptake of HIV-1 by dendritic cells [25]), then the course of disease in monkeys CH56, CH57, and CH83 might represent the net result of inhibition by neutralization and enhancement by antibody-mediated cellular uptake. Interestingly, monkey CH46, who fared somewhat better than the others and lacked virus in the liver and spleen, did not show the presence of large immunoreactive monocytes. This is suggestive of lowered Fc receptor-mediated uptake of virus or reduced activity of the mononuclear phagocytic system.
###end p 20
###begin title 21
Discussion
###end title 21
###begin p 22
###xml 52 57 <span type="species:ncbi:9606">human</span>
Here, we describe the case of a potent neutralizing human monoclonal antibody, administered to give a high serum concentration, which is shown to be unable to protect macaques against challenge with a lethal dose of ZEBOV. The antibody appeared to have very little effect on the course of virus replication or disease in three of four treated animals. Neutralization escape does not appear to explain the lack of protection observed by the antibody. In one animal, a more limited infection was observed, but this macaque did also eventually succumb to the effects of viral disease.
###end p 22
###begin p 23
###xml 259 260 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 66 70 <span type="species:ncbi:205488">EBOV</span>
The challenge dose of 1,000 pfu used corresponds to the amount of EBOV contained in a relatively small quantity of fluid (on the order of 1 mul) from an infected individual given the high titers of virus typically found in such individuals (on the order of 106 pfu/ml of blood, for example). Therefore, the challenge dose was not unreasonable in terms of a natural exposure to virus.
###end p 23
###begin p 24
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b026">26</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b027">27</xref>
###xml 1011 1012 1011 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b006">6</xref>
###xml 1066 1067 1066 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b008">8</xref>
###xml 1512 1514 1512 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b014">14</xref>
###xml 1908 1909 1908 1909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b002">2</xref>
###xml 97 101 <span type="species:ncbi:205488">EBOV</span>
###xml 512 516 <span type="species:ncbi:205488">EBOV</span>
###xml 926 936 <span type="species:ncbi:10141">guinea pig</span>
###xml 1030 1034 <span type="species:ncbi:205488">EBOV</span>
###xml 1425 1430 <span type="species:ncbi:9606">human</span>
###xml 2096 2106 <span type="species:ncbi:10141">guinea pig</span>
The negative results with passive antibody contrast strongly with recent successes in preventing EBOV infection in macaques through vaccination [26,27]. Does this mean that neutralizing antibody is unimportant in vaccine protection? The answer to this question must await further studies. However, a plausible hypothesis to explain all the data would still allow for an important contribution of antibody to vaccine protection. This hypothesis would argue that passive antibody is unable to completely block all EBOV entry to cells, and once a few cells are infected, virus replication is so explosive that it cannot be contained by a de novo generated cellular immune response. Vaccination, on the other hand, will provide CD8+ memory T cells that can be rapidly recruited to become effector cells and limit infection. Certainly, although mAb KZ52 was able to provide protection from disease following ZEBOV challenge in the guinea pig model, immunity was not sterilizing and some viral replication was noted [6]. Since 1 pfu of EBOV is a lethal dose for primates [8], a failure of passive antibody to achieve sterilizing immunity may be critical. Immunohistochemistry, as discussed above, gives some intriguing hints that uptake of antibody-coated virions by monocytes may possibly have a role to play in the course of infection following antibody treatment. We note, however, that previous in vitro studies using isolated human monocytes/macrophages did not find evidence of infectivity-enhancing antibodies [14]. More detailed in vitro and in vivo investigations will be required before any firm conclusions can be drawn. We also note that our experiments were carried out with a single neutralizing monoclonal antibody. It is possible that a more favorable outcome may have been apparent for a combination of neutralizing antibodies or even a combination of neutralizing and nonneutralizing antibodies [2]. However, these possibilities should be weighed against the very high concentrations of neutralizing monoclonal antibody used in the experiments and the efficacy of the antibody in the guinea pig model.
###end p 24
###begin p 25
###xml 395 399 <span type="species:ncbi:205488">EBOV</span>
In summary, the inability of high concentrations of neutralizing antibody to even slow viral replication in infected macaques is remarkable and implies a mechanism of infection propagation that is virtually insensitive to antibody. Overall, the results suggest that monoclonal antibody prophylaxis or post-exposure prophylaxis alone are unlikely to be effective strategies in protecting against EBOV, for example, following a needle-stick accident in a research setting or a bioterrorist attack.
###end p 25
###begin title 26
Materials and Methods
###end title 26
###begin title 27
Passive transfer experiment.
###end title 27
###begin p 28
###xml 38 40 38 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b011">11</xref>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 69 84 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 343 354 <span type="species:ncbi:205488">Ebola virus</span>
50 mg/kg of KZ52 IgG1 human antibody [11] was given intravenously to rhesus macaques (weight, 3.9-4.4 kg) 1 d before challenge (day 0) with 1,000 pfu intramuscularly of the 1995 ZEBOV (Kikwit) isolate and again 4 d later (day +4). One monkey was not given any antibody treatment. The animals were carefully monitored for signs of disease, and Ebola virus plasma viremia was determined at days 4, 7, 9, and 10 in serum by plaque assay as described below.
###end p 28
###begin p 29
###xml 33 81 33 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Guide for the Care and Use of Laboratory Animals</italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b028">28</xref>
The investigators adhered to the Guide for the Care and Use of Laboratory Animals when conducting research, using animals [28]. The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) animal facilities and animal care and use program are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. All infectious material and animals were handled in a maximum-containment biosafety level 4 facility at USAMRIID under standard operating conditions.
###end p 29
###begin title 30
Antibody purification.
###end title 30
###begin p 31
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b029">29</xref>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Limulus</italic>
IgGl KZ52 was produced and purified as described by Parren et al. [29] and was >98% pure, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and contained <1 IU of endotoxin/ml, as determined in a quantitative chromagenic Limulus amoebecyte lysate assay (BioWhittaker, Cambrex, ).
###end p 31
###begin title 32
Viremia determined by plaque assay.
###end title 32
###begin p 33
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b013">13</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b021">21</xref>
Plasma viremia and viral loads in organs was determined by virus titration in a conventional plaque assay on Vero E6 cells, as described elsewhere [13,21].
###end p 33
###begin title 34
Neutralization assay.
###end title 34
###begin p 35
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 284 286 284 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 561 562 555 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1021 1023 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b011">11</xref>
###xml 1024 1026 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b030">30</xref>
###xml 111 117 <span type="species:ncbi:9913">bovine</span>
Samples were diluted into Eagle's minimal essential medium (EMEM; Invitrogen, ) with 5% heat-inactivated fetal bovine serum (FBS). In the presence and absence of a constant dilution of 1:10 or 1:100 of 4 mg/ml KZ52 (thus, 0.4 mg/ml or 0.04 mg/ml), plasma were titrated from 10-1 to 10-6 dilutions. Viremia was determined by counting pfu on Vero E6 cell monolayers. Cells grown to confluence in 6-well plates were given 0.2 ml of plasma with and without additional KZ52. The titrated samples were incubated in the presence of KZ52 for 1 h at 37 degreesC in 5% CO2. After absorption, the cells were overlaid with 2 ml of EMEM containing 5% FBS, 25 mM HEPES buffer, 50-mug gentamicin per ml, and 1% agarose. After 10 d, plaques were visible and the cells were removed from the humidified 37 degreesC incubator to visualize plaques with an inverted phase microscope. 2 ml of neutral red (1:6,000 final concentration; Sigma-Aldrich, ) was added to each well, and after an additional 24-h incubation, the plaques were counted [11,30].
###end p 35
###begin title 36
ELISA.
###end title 36
###begin p 37
###xml 846 847 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1088 1089 1079 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1031 1035 <span type="species:ncbi:9925">goat</span>
###xml 1041 1046 <span type="species:ncbi:9606">human</span>
Nunc-Immuno Maxisorp enzyme-linked immunosorbent assay (ELISA) plates (Nunc, ) were coated with 100 mul/well of 10 mug/ml lectin from Galanthus Nivalis (Sigma-Aldrich) in PBS and incubated overnight at 4 degreesC. The plates were then blocked in phosphate-buffered saline (PBS) containing 10% FBS for 2 h. The wells were then washed twice with wash buffer, PBS containing 0.2% Tween 20 (Sigma-Aldrich). 293 cells were transfected with a mammalian expression plasmid coding for transmembrane domain-deleted Ebola glycoprotein. Supernatant (100 mul) from these cells, which contains 0.8-1.3 mg/ml total protein, was used to coat each well for 1 h at room temperature (RT) after the blocking solution was removed from the ELISA plates. Plates were then washed six times with wash buffer. Monkey sera were added in 10-fold dilutions from 1:10 to 1:105 in dilution buffer (PBS containing 1% BSA and 0.02% Tween) and incubated at RT for 1 h. The wells were then washed six times, and a secondary antibody alkaline phosphatase-conjugated goat anti-human immunoglobulin G (IgG) against the F(ab')2 portion of the antibody (Pierce, ) diluted 1:500 was added, and this was incubated for 1 h. Finally, the plates were washed again six times and developed by one tablet of phosphatase substrate (Sigma-Aldrich) in 5 ml of alkaline phosphatase stain buffer (pH 9.8) per plate. The assay was performed as per manufacturer's directions. The plates were read at an optical density of 405 nm on a microplate reader (Molecular Devices, ) at 30 min after adding substrate. A panel of normal sera was run each time the assay was performed.
###end p 37
###begin title 38
Immunohistochemistry.
###end title 38
###begin p 39
###xml 972 974 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b015">15</xref>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 398 402 <span type="species:ncbi:205488">EBOV</span>
###xml 806 810 <span type="species:ncbi:205488">EBOV</span>
Sections were pretreated with Dako Ready to Use Proteinase K (Dako, ) for 6 min at RT after deparaffinization and rehydration through a series of graded ethanols. Blocking was performed with Dako's Serum-Free Protein Block for 20 min pre-antibody exposure. The tissue sections were then incubated overnight at 4 degreesC in primary antibody using an equal mixture of mouse monoclonal antibodies to EBOV GP and VP40 (1:5,000). An alkaline phosphatase-labeled polymer (Dako Envision System, alkaline phosphatase) was incubated on the sections for 30 min, and then color was developed by exposing tissue to 6-bromo-2-hydroxyl-3-naphtholic acid (HistoMark Red; Kikegaard and Perry Laboratories, ) substrate for 50 min in the dark. Counterstaining was done with hematoxylin. Positive controls included archived EBOV-infected cynomolgus tissue, and negative controls included replicate sections exposed to anti-Marburg virus antibodies and uninfected cynomolgus macaque tissue [15].
###end p 39
###begin p 40
We are grateful to Ann Hessell and Paul Carney for antibody production.
###end p 40
###begin title 41
Abbreviations
###end title 41
###begin p 42
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus
###end p 42
###begin p 43
inhibitory concentration
###end p 43
###begin p 44
50% lethal dose
###end p 44
###begin p 45
monoclonal antibody
###end p 45
###begin p 46
plaque-forming unit
###end p 46
###begin p 47
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire Ebola</italic>
###xml 0 17 <span type="species:ncbi:186538">Zaire Ebola virus</span>
Zaire Ebola virus
###end p 47
###begin title 48
References
###end title 48
###begin article-title 49
Return to the past: The case for antibody-based therapies in infectious diseases
###end article-title 49
###begin article-title 50
The antiviral activity of antibodies in vitro and in vivo
###end article-title 50
###begin article-title 51
Antiviral antibody responses: The two extremes of a wide spectrum
###end article-title 51
###begin article-title 52
###xml 41 52 <span type="species:ncbi:121791">Nipah virus</span>
Antibody prophylaxis and therapy against Nipah virus infection in hamsters
###end article-title 52
###begin article-title 53
Induction of protective cytotoxic T-cell responses in the presence of high titers of virus-neutralizing antibodies: Implications for passive and active immunization
###end article-title 53
###begin article-title 54
###xml 38 49 <span type="species:ncbi:205488">Ebola virus</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody
###end article-title 54
###begin article-title 55
Antibodies, viruses, and vaccines
###end article-title 55
###begin article-title 56
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Filoviridae:</italic>
Filoviridae: Marburg and Ebola viruses
###end article-title 56
###begin article-title 57
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients
###end article-title 57
###begin article-title 58
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
Ebola virus can be effectively neutralized by antibody produced in natural human infection
###end article-title 58
###begin article-title 59
###xml 24 35 <span type="species:ncbi:205488">Ebola virus</span>
###xml 45 63 <span type="species:ncbi:9541">cynomolgus monkeys</span>
###xml 101 107 <span type="species:ncbi:9796">horses</span>
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses
###end article-title 59
###begin article-title 60
###xml 95 106 <span type="species:ncbi:205488">Ebola virus</span>
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections
###end article-title 60
###begin article-title 61
###xml 75 86 <span type="species:ncbi:205488">Ebola virus</span>
Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections
###end article-title 61
###begin article-title 62
Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells
###end article-title 62
###begin article-title 63
###xml 13 24 <span type="species:ncbi:205488">Ebola virus</span>
###xml 105 119 <span type="species:ncbi:9544">rhesus monkeys</span>
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys
###end article-title 63
###begin article-title 64
Development and study of the properties of immunoglobulin against Ebola fever
###end article-title 64
###begin article-title 65
###xml 72 83 <span type="species:ncbi:205488">Ebola virus</span>
Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections
###end article-title 65
###begin article-title 66
Developing principles for emergency prevention and treatment of Ebola fever
###end article-title 66
###begin article-title 67
###xml 108 113 <span type="species:ncbi:9606">human</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
###end article-title 67
###begin article-title 68
###xml 29 40 <span type="species:ncbi:205488">Ebola virus</span>
###xml 54 65 <span type="species:ncbi:10141">guinea pigs</span>
Pathogenesis of experimental Ebola virus infection in guinea pigs
###end article-title 68
###begin article-title 69
###xml 64 75 <span type="species:ncbi:205488">Ebola virus</span>
An analysis of features of pathogenesis in two animal models of Ebola virus infection
###end article-title 69
###begin article-title 70
Marburg and Ebola hemorrhagic fevers: Does the primary course of infection depend on the accessibility of organ-specific macrophages?
###end article-title 70
###begin article-title 71
Molecular pathogenesis of filovirus infections: Role of macrophages and endothelial cells
###end article-title 71
###begin article-title 72
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Viral piracy: HIV-1 targets dendritic cells for transmission
###end article-title 72
###begin article-title 73
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
###end article-title 73
###begin article-title 74
###xml 28 39 <span type="species:ncbi:205488">Ebola virus</span>
Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman primates
###end article-title 74
###begin article-title 75
###xml 81 109 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
###end article-title 75
###begin article-title 76
###xml 0 11 <span type="species:ncbi:11620">Lassa virus</span>
###xml 25 39 <span type="species:ncbi:9544">rhesus monkeys</span>
Lassa virus infection of rhesus monkeys: Pathogenesis and treatment with ribavirin
###end article-title 76
###begin title 77
Figures and Tables
###end title 77
###begin title 78
Plasma Viremia in Macaques Challenged with ZEBOV
###end title 78
###begin p 79
###xml 37 39 37 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b011">11</xref>
###xml 265 270 <span type="species:ncbi:9606">human</span>
###xml 317 332 <span type="species:ncbi:9544">rhesus macaques</span>
Shown is the measured viremia, in log10 pfu per ml, for four antibody-treated monkeys (CH46, CH56, CH57, and CH83) and one untreated control animal (EHD) at days 4, 7, 9, and 10 in plasma by plaque assay as described in Materials and Methods. 50 mg/kg of KZ52 IgG1 human antibody [11] was given intravenously to four rhesus macaques 1 d before and again 4 d after challenge with 1,000 pfu (intramusculary) of the 1995 ZEBOV (Kikwit) isolate. Ab, antibody.
###end p 79
###begin title 80
A Large Immunoreactive Monocyte Is Observed in a Blood Vessel in the Kidney of Monkey CH57 Postmortem
###end title 80
###begin p 81
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030009-b015">15</xref>
Similar cells were observed in analysis of monkeys CH83 and CH56. Typically smaller immunoreactive monocytes are seen with ZEBOV infection [15]. Immunohistochemistry was performed as described in Materials and Methods.
###end p 81
###begin p 82
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human KZ52 Antibody Titers in Rhesus Macaques Pre-Treatment 1 d before Challenge with ZEBOV (Day -1) and Pre-Boost 4 d after Challenge with ZEBOV (Day 4)
###end p 82
###begin p 83
Posthumous Viral Loads in Specific Organs of Rhesus Macaques
###end p 83
###begin p 84
currencya Current address: Charles River Laboratories, Preclinical Services, Redfield, Arkansas, United States of America
###end p 84
###begin p 85
currencyb Current address: Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
###end p 85
###begin p 86
currencyc Current address: Genmab, Utrecht, The Netherlands
###end p 86
###begin p 87
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 87
###begin p 88
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. TWG, PBJ, PWHIP, and DRB conceived and designed the experiments. TWG, KJD, JBG, NJS, PBJ, and PWHIP performed the experiments. WBO, TWG, PBJ, PWHIP, and DRB analyzed the data. TWG, KJD, and NJS contributed reagents/materials/analysis tools. WBO and DRB wrote the paper.
###end p 88
###begin p 89
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported in part by grant A148053 from the US National Institutes of Health.
###end p 89

